← Back to The Absolute Effect
Testicular Germ-Cell Tumours · Medical Oncology · First relapse after BEP · second-line salvage

MRC phase II TIP study

After first relapse following BEP, what response and survival outcomes were observed with TIP?

Mixed metastatic GCT cohort

Population
43 assessable

Study population as reported in the cited publication; cohort sizes and denominators are stated where available.

Evidence type
Mixed GCT

Not all evidence is randomized, comparative, or seminoma-specific.

Reported outcomes

Four cycles of TIP were evaluated in a UK MRC phase II study. Among 43 patients assessable for response, 8 achieved CR and 18 achieved marker-negative partial remission (favourable response 60%; 95% CI 44–75%). One-year survival was 70% and failure-free survival 36%.

Favourable response (CR + marker-negative PR)26/43
1-year overall survival70%
1-year failure-free survival36%

Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.

Interpretation and limitations

This regimen schedule produced lower response results than the original single-centre Kondagunta TIP series; differences in dose intensity and growth-factor support are important. Histology was mixed, not seminoma-only.

Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.

Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025

Primary study source

Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP given as second-line (post-BEP) salvage chemotherapy for metastatic germ cell cancer: an MRC trial. Br J Cancer. 2005;93:178–184.

Original study / PubMed / registry ↗

Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.